Dan has 10 years’ experience as a technical, hands-on health economist in both consulting and industry, and has specialised in oncology and rare disease modelling across a breadth of indications, leading on or contributing to over 20 HTA submissions. Dan is also experienced in the development of indirect treatment comparisons in the context of single-arm oncology trials, which are becoming all the more common with accelerated regulatory pathways and corresponding earlier reimbursement timelines.
Dan has an MSc in Health Economics and Decision Modelling from the University of Sheffield and an MPhil in Neuroscience from the University of Manchester.
